Publications

ePoster presented at 51. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany. [Virtual].

Health Expect. 2021 Oct;24(5):1790-1800

Chronic visible skin diseases are highly prevalent, and patients affected frequently report feeling stigmatised. Interventions to reduce stigmatisation are rare.

Objectives: This study aimed to evaluate the effectiveness of a structured short intervention in reducing stigmatising attitudes towards psoriasis in future educators.

ePoster presented at 51. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany. [Virtual].

J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1553-1561

60–90% of patients with psoriasis suffer from pruritus and 65% report itching as one of the most burden- some symptoms, raising significant quality of life (QoL) impairments. However, pruritus is not only an intrapersonal symptom but also a psychosocial interactive phenomenon and little is known about the effects of itching on interpersonal experiences.

Objectives: This study aimed to compare the disease burden and patient needs between patients with none/mild vs. moderate/severe pruritus, and to examine the impact of disease parameters and intrapersonal burden on perceived stigmatization and sexual relationships.

J Eur Acad Dermatol Venereol. 2021 Nov 24

Misconceptions about visible skin diseases are widespread, and patients often face discrimination and stigmatization due to their condition. The associated negative health and psychosocial consequences of stigmatization in skin diseases have prompted an increase in research activity in recent times, resulting in a wide variety of assessment measures. This study aimed at aggregating and evaluating evidence of psychometric properties and methodological quality of published measures to assess stigma in visible skin diseases.

J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2241-2249

Cross-cultural differences in healthcare policies and patient–physician communication may influence the quality of care and patients’ perceived benefits and satisfaction with psoriasis treatment.

 J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2166-2184

Patients with chronic skin diseases suffer from physical and psychosocial impairments which can lead to a cumulative life-long burden. Therefore, the concept of cumulative life course impairment (CLCI) was introduced, referring to the non- reversible damage due to the persistent life-long burden. This systematic review (PROSPERO registry number: CRD42020179141) aimed at mapping the risk factors and the associated burden over time in patients with psoriasis, ato- pic dermatitis (AD) and hidradenitis suppurativa (HS).

6th World Psoriasis & Psoriatic Arthritis Conference, 2021; keynote lecture.

Jahrestagung des Arbeitskreises Psychosomatische Dermatologie; 2021.

Patient Prefer Adherence. 2021 Jul 14;15:1571-1578

The questionnaire for the quality of life with chronic wounds (Wound-QoL) is a valid and reliable instrument to determine the disease-specific health-related QoL of patients with chronic wounds. For the interpretation of HRQoL scores, it is additionally important to know which differences in scores are considered meaningful. The minimal important difference (MID) is defined as a change in HRQoL that a patient would consider meaningful, such that the patient would judge a treatment to be beneficial and worthy of repeating.